Absence of MxA induction by interferon β in patients with MS reflects complete loss of bioactivity

Neurology

Volumn 73, Issue 5, 2009, Pages 372-377

  Hesse, D ^a   Sellebjerg, F ^a   Sorensen, P Soelberg ^a  

^a Mental Health Services CPH   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; MYXOVIRUS RESISTANCE PROTEIN A; NEUTRALIZING ANTIBODY;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; DRUG ACTIVITY; DRUG EFFECT; DRUG RESPONSE; FEMALE; GENE EXPRESSION; HUMAN; MALE; MONONUCLEAR CELL; MULTIPLE SCLEROSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 68249162126     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181b04c98     Document Type: Article

References (24)

1. Hesse D, Sorensen PS. Using measurements of neutralizing antibodies: the challenge of IFN-beta therapy. Eur J Neurol 2007;14:850-859.
2. Ross C, Clemmesen KM, Sorensen PS, Koch-Henriksen N, Bendtzen K. Measuring and evaluating interferon beta-induced antibodies in patients with multiple sclerosis. Mult Scler 2006;12:39-46.
3. Sorensen PS, Ross C, Clemmesen KM, et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003;362:1184-1191.
4. Sorensen PS, Deisenhammer F, Duda P, et al. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 2005;12:817-827.
5. Goodin DS, Frohman EM, Garmany GP, Jr., et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002;58:169-178.
6. Sorensen PS, Bertolotto A. Re: Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2007;69:1552.
7. Pachner A, Narayan K, Price N, Hurd M, Dail D. MxA gene expression analysis as an interferon-beta bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity. Mol Diagn 2003;7:17-25.
8. Sorensen PS, Tscherning T, Mathiesen HK, et al. Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS. Neurology 2006;67:1681-1683.
9. Bertolotto A, Sala A, Malucchi S, et al. Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies. J Neurol Neurosurg Psychiatry 2004;75:1294-1299.
10. Malucchi S, Gilli F, Caldano M, et al. Predictive markers for response to interferon therapy in patients with multiple sclerosis. Neurology 2008;70:1119-1127.
11. Pachner AR, Dail D, Pak E, Narayan K. The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies. J Neuroimmunol 2005;166:180-188.
12. Deisenhammer F, Reindl M, Harvey J, Gasse T, Dilitz E, Berger T. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 1999;52:1239-1243.
13. Bertolotto A, Gilli F, Sala A, et al. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. Neurology 2003;60:634-639.
14. Sellebjerg F, Datta P, Larsen J, et al. Gene expression analysis of interferon-beta treatment in multiple sclerosis. Mult Scler 2008;14:615-621.
15. Farrell R, Kapoor R, Leary S, et al. Neutralizing antiinterferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta. Mult Scler 2008;14:212-218.
16. Grossberg SE, Kawade Y, Kohase M, Klein JP. The neutralization of interferons by antibody: II: Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit. J Interferon Cytokine Res 2001;21:743-755.
17. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing 2. J R Stat Soc B 1995;57:289-300.
18. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci USA 2003;100:9440-9445.
19. Weinstock-Guttman B, Badgett D, Patrick K, et al. Genomic effects of IFN-beta in multiple sclerosis patients. J Immunol 2003;171:2694-2702.
20. Moll HP, Freudenthaler H, Zommer A, Buchberger E, Brostjan C. Neutralizing type I IFN antibodies trigger an IFN-like response in endothelial cells. J Immunol 2008;180:5250-5256.
21. Reder AT, Velichko S, Yamaguchi KD, et al. IFN-beta1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expression. J Interferon Cytokine Res 2008;28:317-331.
22. Pachner AR, Narayan K, Pak E. Multiplex analysis of expression of three IFNbeta-induced genes in antibody-positive MS patients. Neurology 2006;66:444-446.
23. Sorensen PS, Koch-Henriksen N, Ross C, Clemmesen KM, Bendtzen K. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005;65:33-39.
24. Sorensen PS. Management of patients with neutralizing antibodies against interferon-beta: stop IFN-beta therapy or wait for the antibodies to go away? Eur J Neurol 2009;16:1-2.